Compare AIRE & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIRE | MBRX |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | 54 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 13.1M |
| IPO Year | 2023 | 2016 |
| Metric | AIRE | MBRX |
|---|---|---|
| Price | $2.12 | $2.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $1.30 | ★ $61.00 |
| AVG Volume (30 Days) | 151.8K | ★ 265.7K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.34 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,518,498.00 | N/A |
| Revenue This Year | $129.06 | N/A |
| Revenue Next Year | $83.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 376.42 | N/A |
| 52 Week Low | $0.14 | $0.25 |
| 52 Week High | $3.98 | $7.98 |
| Indicator | AIRE | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.49 | 47.30 |
| Support Level | $0.31 | $2.24 |
| Resistance Level | $3.98 | $2.64 |
| Average True Range (ATR) | 0.24 | 0.21 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 27.84 | 42.69 |
ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are Homebuying Services and the Technology Services segment.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.